The present invention is a biphenylamidine derivative represented by the formula (1) or a pharmaceutically acceptable derivative thereof:
and the biphenylamidine derivative or the pharmaceutically acceptable derivative thereof is a novel compound which can be used as a clinically applicable FXa inhibitor.
Methano-bridged 14.pi.-electron aromatic annulenes. 2. 5-Methoxy-7,12-methano-6-azabenz[10]annulene and the benzenesulfonate ester of 5-hydroxy-7,12-methano-6-azabenz[10]annulene